Last reviewed · How we verify
Gemcitabine and Oxaliplatin
Gemcitabine and oxaliplatin work together as a chemotherapy combination to damage cancer cell DNA and prevent cell division through complementary mechanisms.
Gemcitabine and oxaliplatin work together as a chemotherapy combination to damage cancer cell DNA and prevent cell division through complementary mechanisms. Used for Pancreatic cancer, Colorectal cancer, Biliary tract cancer.
At a glance
| Generic name | Gemcitabine and Oxaliplatin |
|---|---|
| Also known as | gemcitabine 1000mg/m2 IV q2week and oxaliplatin 85mg/m2 IV q2week, GemOx |
| Sponsor | New Mexico Cancer Research Alliance |
| Drug class | Chemotherapy combination (nucleoside analog + platinum agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. Oxaliplatin is a platinum-based agent that forms DNA cross-links, preventing replication and transcription. The combination leverages synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Pancreatic cancer
- Colorectal cancer
- Biliary tract cancer
- Gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Fatigue
- Mucositis
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine and Oxaliplatin CI brief — competitive landscape report
- Gemcitabine and Oxaliplatin updates RSS · CI watch RSS
- New Mexico Cancer Research Alliance portfolio CI